Ovarian hyperstimulation syndrome (OHSS): New strategies of prevention and treatment

Journal of the Formosan Medical Association

Volumn 107, Issue 7, 2008, Pages 509-512

  Chen, Shee Uan ^a   Chen, Chin Der ^a   Yang, Yu Shih ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CABERGOLINE; CHORIONIC GONADOTROPIN; ESTRADIOL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; INTERLEUKIN 6; INTERLEUKIN 8; LUTEINIZING HORMONE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; PROGESTERONE; RECOMBINANT LUTEINIZING HORMONE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CRYOPRESERVATION; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG HALF LIFE; EMBRYO TRANSFER; ENDOTHELIUM CELL; FEMALE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY THERAPY; NIDATION; NONHUMAN; OOCYTE MATURATION; OVARY FOLLICLE FLUID; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PATHOPHYSIOLOGY; PREGNANCY; PROTEIN SECRETION; PROTEIN SYNTHESIS; RAT; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 50049125108     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(08)60162-X     Document Type: Article

References (11)

1. Alvarez C, Martí-Bonmatí L, Novella-Maestre E, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007;92:2931-7.
2. Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome - views and ideas. Hum Reprod 1997;12:1129-37.
3. Chen SU, Chou CH, Lee HY, et al. Lysophosphatidic acid up-regulates expression of interleukin-8 and -6 in human granulosa-lutein cells through LPA receptors and NF-κB dependent pathways: implications for angiogenesis of corpus luteum and ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 2008;93:935-43.
4. Chen CD, Chao KH, Yang JH, et al. Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome. Fertil Steril 2003;80:86-90.
5. European Recombinant LH Study Group. Recombinant human luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab 2001;86:2607-18.
6. Nargund G, Hutchison L, Scaramuzzi R, et al. Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles. Reprod Biomed Online 2007;14:682-5.
7. Engmann L, DiLuigi A, Schmidt D, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008;89:84-91.
8. Villasante A, Pacheco A, Ruiz A, et al. Vascular endothelial cadherin regulates vascular permeability: implications for ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 2007;92:314-21.
9. Basu S, Nagy JA, Pal S, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001;7: 569-74.
10. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147:5400-11.
11. Alvarez C, Alonso-Muriel I, García G, et al. Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007;22:3210-4.